{"symbol": "BPMC", "companyName": "Blueprint Medicines Corporation", "exchange": "Nasdaq Global Select", "industry": "Biotechnology", "website": "http://www.blueprintmedicines.com", "description": "Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.", "CEO": "Jeffrey W. Albers", "issueType": "cs", "sector": "Healthcare", "tags": ["Healthcare", "Biotechnology"]}